<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="034bf68c-288b-4943-8ce7-045afa12b4ec"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use OZURDEX</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for OZURDEX</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold">.</content>
      <br/>
      <content styleCode="bold">  </content>
      <br/>
      <content styleCode="bold">OZURDEX</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (dexamethasone intravitreal implant)</content>
      <content styleCode="bold">,</content>
      <content styleCode="bold"> </content>
      <br/>
      <content styleCode="bold">f</content>
      <content styleCode="bold">or </content>
      <content styleCode="bold">i</content>
      <content styleCode="bold">ntravitreal </content>
      <content styleCode="bold">i</content>
      <content styleCode="bold">njection</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1958</content>
      <br/>
   </title>
   <effectiveTime value="20250520"/>
   <setId root="4b204f44-6e8a-4d17-803c-268f0b04679f"/>
   <versionNumber value="29"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="144796497" root="1.3.6.1.4.1.519.1"/>
            <name>Allergan, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9fe1f176-f03e-4431-872c-760c70868ce9"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250521"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0023-3348" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>OZURDEX</name>
                        <formCode code="C42942" displayName="IMPLANT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dexamethasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXAMETHASONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXAMETHASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" displayName="POUCH" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-3348-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090901"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43200" displayName="POUCH" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-3348-08" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090901"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022315" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090901"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38280" displayName="INTRAVITREAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="713315ab-6d64-48ba-a62e-882cbdbaec6a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">
		     
	INDICATIONS AND USAGE</content>
               </title>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> is a corticosteroid indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) (<linkHtml href="#_1_1_Retinal_Vein">1.1</linkHtml>)<br/>
                           </item>
                           <item>The treatment of non-infectious uveitis affecting the posterior segment of the eye (<linkHtml href="#_1_2_Posterior_Segment">1.2</linkHtml>)<br/>
                           </item>
                           <item>The treatment of diabetic macular edema (<linkHtml href="#_1_3_Diabetic_Macular">1.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_1_1_Retinal_Vein">
                     <id root="8a5a6474-7380-4553-a769-a21ff637b87a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1</content>
		     
	<content styleCode="bold">Retinal Vein Occlusion</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> </content>(dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_2_Posterior_Segment">
                     <id root="8f24aecd-56e3-4b15-9ac7-0ff73ded53fa"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.2</content>
		     
	<content styleCode="bold">Posterior Segment Uveitis</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> </content>is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_3_Diabetic_Macular">
                     <id root="578e6f09-0597-43b4-b94a-084c652b9b48"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.3</content>
		     
	<content styleCode="bold">Diabetic Macular Edema </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> </content>is indicated for the treatment of diabetic macular edema.  </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6d3dbc87-a85f-4e52-8282-31a28aa3c771"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2  </content>
                  <content styleCode="bold">
		     
	DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>For ophthalmic intravitreal injection. (<linkHtml href="#_2_1_General_Dosing">2.1</linkHtml>) <br/>
                           </item>
                           <item>The intravitreal injection procedure should be carried out under controlled aseptic conditions. (<linkHtml href="#_2_2_Administration">2.2</linkHtml>) <br/>
                           </item>
                           <item>Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. (<linkHtml href="#_2_2_Administration">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_General_Dosing">
                     <id root="faa914ed-4293-4b55-8e9f-65d0ed12dd02"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
		     
	<content styleCode="bold">General Dosing Information</content>
                     </title>
                     <text>
                        <paragraph>For ophthalmic intravitreal injection.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Administration">
                     <id root="e14b1fab-9c64-45f4-865d-bcf3d4baa356"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
		     
	<content styleCode="bold">Administration</content>
                     </title>
                     <text>
                        <paragraph>The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide applied to the periocular skin, eyelid and ocular surface are recommended to be given prior to the injection. </paragraph>
                        <paragraph>Remove the foil pouch from the carton and examine for damage. Then, open the foil pouch over a sterile field and gently drop the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator. <content styleCode="bold">Do not twist or flex the tab</content>
                           <content styleCode="bold">.</content> The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus), then re-directed toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva.</paragraph>
                        <paragraph>Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous.</paragraph>
                        <paragraph>Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay. </paragraph>
                        <paragraph>Each applicator can only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new applicator must be used, and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed before <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> is administered to the other eye. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3__DOSAGE">
               <id root="3f3697a1-69bf-40c5-bcd7-4b38a83eea01"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 </content>
                  <content styleCode="bold">
		     
	DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Intravitreal implant containing dexamethasone 0.7 mg in the <content styleCode="bold">N</content>
                     <content styleCode="bold">OVADUR</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> solid polymer drug delivery system.</paragraph>
               </text>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Intravitreal implant containing dexamethasone 0.7 mg in the <content styleCode="bold">NOVADUR</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> solid polymer drug delivery system.<content styleCode="bold"> </content>(<linkHtml href="#_3__DOSAGE">3</linkHtml>)<content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="ebc24665-017b-441b-bff4-5abcd0efa7d6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ocular or periocular infections (<linkHtml href="#_4_1_Ocular_or">4.1</linkHtml>)<br/>
                           </item>
                           <item>Glaucoma (<linkHtml href="#_4_2_Glaucoma">4.2</linkHtml>)<br/>
                           </item>
                           <item>Torn or ruptured posterior lens capsule (<linkHtml href="#_4_3_Torn_or">4.3</linkHtml>)<br/>
                           </item>
                           <item>Hypersensitivity (<linkHtml href="#_4_4_Hypersensitivity">4.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_4_1_Ocular_or">
                     <id root="ac74c260-c975-41d4-9c0d-674c7594b616"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.1</content>
		     
	<content styleCode="bold">Ocular or Periocular Infections</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> </content>(dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_4_2_Glaucoma">
                     <id root="6dcf5a32-489b-4377-8b38-b885e91f8632"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.2</content>
		     
	<content styleCode="bold">Glaucoma</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_4_3_Torn_or">
                     <id root="e2894199-3978-4eb2-8dce-f55f5cf4dece"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.3</content>
		     
	<content styleCode="bold">Torn or Ruptured </content>
                        <content styleCode="bold">Posterior Lens Capsule</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup> is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup> use.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_4_4_Hypersensitivity">
                     <id root="e713ec5f-43f7-4ff5-87fc-9409a899795c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.</content>
                        <content styleCode="bold">4</content>
		     
	<content styleCode="bold">Hypersensitivity</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> is contraindicated in patients with known hypersensitivity to any components of this product <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ec141931-694c-4a7e-9d75-f22f68b0bcf1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (<linkHtml href="#_5_1_Intravitreal_Injection_related">5.1</linkHtml>) <br/>
                           </item>
                           <item>Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. (<linkHtml href="#_5_2_Steroid_related_Effects">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Intravitreal_Injection_related">
                     <id root="41c6769c-f89c-4e8f-bf35-853cbac6a9e1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
		     
	<content styleCode="bold">Intravitreal Injection-related Effects</content>
                     </title>
                     <text>
                        <paragraph>Intravitreal injections, including those with <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup>, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored regularly following the injection <content styleCode="italics">[see Patient Counseling Information (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_17_PATIENT_COUNSELING">17</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Steroid_related_Effects">
                     <id root="b79ad6fe-8904-4850-89e5-609c78d97e1a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2</content>
		     
	<content styleCode="bold">Steroid-related Effects</content>
                     </title>
                     <text>
                        <paragraph>Use of corticosteroids including <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup> may produce posterior subcapsular cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Studies">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6_ADVERSE_REACTIONS">
               <id root="6100155b-51de-4d52-abd5-f8a8dd4e1151"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
               </title>
               <effectiveTime value="20250520"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>In controlled studies, the most common adverse reactions reported by 20–70% of patients were cataract, increased intraocular pressure and conjunctival hemorrhage. (<linkHtml href="#_6_1_Clinical_Studies">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800- 633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>Figure 1: Mean IOP during the study  </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="_6_1_Clinical_Studies">
                     <id root="85dbdd19-4cbf-43c5-88a9-438837e2a68c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
		     
	<content styleCode="bold">Clinical </content>
                        <content styleCode="bold">Trials</content>
                        <content styleCode="bold"> Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse reactions associated with ophthalmic steroids including <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup> include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Retinal Vein Occlusion and Posterior Segment Uveitis</content>
                        </paragraph>
                        <paragraph>The following information is based on the combined clinical trial results from 3 initial, randomized, 6-month, sham-controlled studies (2 for retinal vein occlusion and 1 for posterior segment uveitis):</paragraph>
                        <table>
                           <caption>Table 1: Adverse Reactions Reported by Greater than 2% of Patients</caption>
                           <col width="216"/>
                           <col width="114"/>
                           <col width="102"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">MedDRA Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">OZURDEX</content>
                                    <content styleCode="bold">
                                       <sup>®</sup>
                                    </content>
                                    <br/>N=497 (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Sham</content>
                                    <br/>N=498 (%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Intraocular pressure increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">125 (25%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Conjunctival hemorrhage</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">108 (22%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">79 (16%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Eye pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">40 (8%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26 (5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Conjunctival hyperemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33 (7%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27 (5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Ocular hypertension</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Cataract</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Vitreous detachment</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19 (4%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 (2%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Increased IOP with <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> required surgical procedures for management of elevated IOP.</paragraph>
                        <paragraph>Following a second injection of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> in cases where a second injection was indicated, the overall incidence of cataracts was higher after 1 year.</paragraph>
                        <paragraph>In a 2 year observational study, among patients who received &gt;2 injections, the most frequent adverse reaction was cataract 54% (n= 96 out of 178 phakic eyes at baseline). Other frequent adverse reactions from the 283 treated eyes, regardless of lens status at baseline, were increased IOP 24% (n = 68) and vitreous hemorrhage 6.0% (n = 17).  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Diabetic Macular Edema</content>
                        </paragraph>
                        <paragraph>The following information is based on the combined clinical trial results from 2 randomized, 3-year, sham-controlled studies in patients with diabetic macular edema. Discontinuation rates due to the adverse reactions listed in Table 2 were 3% in the <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> group and 1% in the Sham group. The most common ocular (study eye) and non-ocular adverse reactions are shown in Tables 2 and 3:</paragraph>
                        <table>
                           <caption>Table 2: Ocular Adverse Reactions Reported by ≥ 1% of Patients and Non-ocular Adverse Reactions Reported by ≥ 5% of Patients</caption>
                           <col width="316"/>
                           <col width="147"/>
                           <col width="147"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">MedDRA Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">OZURDEX</content>
                                    <content styleCode="bold">
                                       <sup>®</sup>
                                    </content>
                                    <br/>N=324 (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Sham</content>
                                    <br/>N=328 (%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Ocular</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Cataract<sup>1</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">166/243<sup>2</sup>  (68%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">49/230 (21%) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Conjunctival hemorrhage</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">73 (23%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">44 (13%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Visual acuity reduced</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">28 (9%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">13 (4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Conjunctivitis</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">19 (6%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">8 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Vitreous floaters</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">16 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Conjunctival edema</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">15 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Dry eye</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">15 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">7 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Vitreous detachment</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">14 (4%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">8 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Vitreous opacities</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">11 (3%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Retinal aneurysm</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">10 (3%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Foreign body sensation</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">7 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Corneal erosion</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">7 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Keratitis</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Anterior Chamber Inflammation</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0 (0%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Retinal tear</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Eyelid ptosis</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Non-ocular</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Hypertension</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">41 (13%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">21 (6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">Bronchitis</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">15 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">8 (2%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup> Includes cataract, cataract nuclear, cataract subcapsular, lenticular opacities in patients who were phakic at baseline. Among these patients, 61% of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> subjects vs. 8% of sham-controlled subjects underwent cataract surgery.</paragraph>
                        <paragraph>
                           <sup>2</sup> 243 of the 324 <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> subjects were phakic at baseline; 230 of 328 sham-controlled subjects were phakic at baseline. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Increased Intraocular Pressure</content>
                        </paragraph>
                        <table>
                           <caption>Table 3: Summary of Elevated Intraocular Pressure (IOP) Related Adverse Reactions</caption>
                           <col width="411"/>
                           <col width="153"/>
                           <col width="153"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">IOP</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold"> Treatment: N (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">OZURDEX</content>
                                    <content styleCode="bold">
                                       <sup>®</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">N=324</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Sham</content>
                                    <br/>
                                    <content styleCode="bold">N=328</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">IOP elevation ≥10 mm Hg from Baseline at any visit</td>
                                 <td styleCode="Toprule Lrule Rrule ">91 (28%)</td>
                                 <td styleCode="Toprule Lrule Rrule ">13 (4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">≥30 mm Hg IOP at any visit</td>
                                 <td styleCode="Toprule Lrule Rrule ">50 (15%)</td>
                                 <td styleCode="Toprule Lrule Rrule ">5 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Any IOP lowering medication</td>
                                 <td styleCode="Toprule Lrule Rrule ">136 (42%)</td>
                                 <td styleCode="Toprule Lrule Rrule ">32 (10%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Any surgical intervention for elevated IOP * </td>
                                 <td styleCode="Toprule Lrule Rrule ">4 (1.2%)</td>
                                 <td styleCode="Toprule Lrule Rrule ">1 (0.3%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup>: 1 surgical trabeculectomy for steroid-induced IOP increase, 1 surgical trabeculectomy for iris neovascularization, <br/>1 laser iridotomy, 1 surgical iridectomy<br/>Sham: 1 laser iridotomy</paragraph>
                        <paragraph>The increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles (at the end of the 6 month period) shown below:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Mean IOP during the study</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000001"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cataracts and Cataract Surgery</content>
                        </paragraph>
                        <paragraph>At baseline, 243 of the 324 <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> subjects were phakic; 230 of 328 sham-controlled subjects were phakic. The incidence of cataract<sup> </sup>development in patients who had a phakic study eye was higher in the <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> group (68%) compared with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> group and 12 months in the Sham group. Among these patients, 61% of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>® </sup>
                           </content>subjects vs. 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and Month 39 (Median Month 21 for <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>® </sup>
                           </content>group and 20 for Sham) of the studies.  </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="85791f08-0292-4328-8f23-881646f4607c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
		     
	<content styleCode="bold">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following reactions have been identified during post-marketing use of <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup> in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to <content styleCode="bold">OZURDEX</content>
                           <sup>®</sup>, or a combination of these factors, include: complication of device insertion resulting in ocular tissue injury including sclera, subconjunctiva, lens and retina (implant misplacement), device dislocation with or without corneal edema, endophthalmitis, hypotony of the eye (associated with vitreous leakage due to injection), and retinal detachment.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="162c5edf-22bc-45ce-9200-72d4d1722b56"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250520"/>
               <component>
                  <section>
                     <id root="656a564d-6950-4486-b603-5da5547ab853"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
		     
	<content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies with <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> in pregnant women. Topical ocular administration of dexamethasone in mice and rabbits during the period of organogenesis produced cleft palate and embryofetal death in mice, and malformations of the abdominal wall/intestines and kidneys in rabbits at doses 5 and 4 times higher than the recommended human ophthalmic dose (RHOD) of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> (0.7 milligrams dexamethasone), respectively. </paragraph>
                        <paragraph>In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Topical ocular administration of 0.15% dexamethasone (0.75 mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. A dose of 0.75 mg/kg/day in the mouse is approximately 5 times an <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> injection in humans (0.7 mg dexamethasone) on a mg/m<sup>2</sup> basis. In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.20 mg/kg/day, on gestational day 6 followed by 0.13 mg/kg/day on gestational days 7-18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. A dose of 0.13 mg/kg/day in the rabbit is approximately 4 times an <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> injection in humans (0.7 mg dexamethasone) on a mg/m<sup>2</sup> basis. A no-observed-adverse-effect-level (NOAEL) was not identified in the mouse or rabbits studies. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d9822cee-281a-4df9-8b02-2f6afcb375e0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">2</content>
		     
	<content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Systemically administered corticosteroids are present in human milk and can suppress growth and interfere with endogenous corticosteroid production or cause other unwanted effects. There is no information regarding the presence of dexamethasone in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with  the mother’s clinical need for <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>® </sup>
                           </content>and any potential adverse effects on the breastfed child from <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1537c117-8e78-418f-9c5f-7bb5a6978ece"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
		     
	<content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness of <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content> in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2d01db22-4830-47f4-9242-d3daf4b821d9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
		     
	<content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="db0ddc03-4a4c-49d1-9099-98389e9f8934"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> is a sterile intravitreal implant containing 0.7 mg (700 mcg) dexamethasone in the <content styleCode="bold">NOVADUR</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> solid polymer sustained-release drug delivery system which does not contain an antimicrobial preservative.</paragraph>
                  <paragraph> <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> is preloaded into a single-use, <content styleCode="bold">DDS</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> applicator to facilitate injection of the rodshaped implant directly into the vitreous. The <content styleCode="bold">NOVADUR</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>system contains two poly D,L-lactide-co-glycolide (PLGA) polymer excipients. Both of these polymer materials have the same PLGA backbone, but the terminal end groups differ between them. One polymer, DL-Lactide and Glycolide (50:50) Copolymer 12000 Ethyl Ester, is ester terminated, and the other DL-Lactide and Glycolide (50:50) Copolymer 12000 Acid is acid terminated. The chemical name for dexamethasone is Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-. Its structural formula is: </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000002"/>
                  </paragraph>
                  <paragraph>MW 392.47; molecular formula: C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>
                  </paragraph>
                  <paragraph>Dexamethasone occurs as a white to cream-colored crystalline powder having not more than a slight odor, and is practically insoluble in water and very soluble in alcohol.</paragraph>
                  <paragraph>The PLGA matrix slowly degrades to lactic acid and glycolic acid. </paragraph>
               </text>
               <effectiveTime value="20250520"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>The structural formula for OZURDEX® is an intravitreal implant containing 0.7 mg (700 mcg) dexamethasone in the NOVADUR® solid polymer sustained-release drug delivery system. OZURDEX® is preloaded into a single-use, DDS® applicator to facilitate injection of the rod-shaped implant directly into the vitreous. The NOVADUR® system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix without a preservative. The chemical name for dexamethasone is Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8f630f7d-1fef-47c0-9aa9-81ed8260c64d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250520"/>
               <component>
                  <section>
                     <id root="4953151b-4969-4df4-a889-1544fce7c094"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
		     
	<content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="54382d9a-53c8-43b7-a35e-d935155b6965"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
		     
	<content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Plasma concentrations were obtained from 21 patients with macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and 21 patients with diabetic macular edema (DME)  prior to dosing and at 4 to 5 additional post-dose timepoints on Days 1, 7, 21, 30, 45, 60, and 90 following the administration of the first intravitreal implant containing 0.7 mg dexamethasone.<content styleCode="italics"> </content>In RVO and DME patients, the majority of plasma dexamethasone concentrations were below the lower limit of quantitation (LLOQ = 50 pg/mL). Plasma dexamethasone concentrations from 12% of samples were above the LLOQ, ranging from 52 pg/mL to 102 pg/mL.<content styleCode="italics"> </content>Plasma dexamethasone concentration did not appear to be related to age, body weight, or sex of patients.</paragraph>
                        <paragraph>In an <content styleCode="italics">in vitro</content> metabolism study, following the incubation of [<sup>14</sup>C]-dexamethasone with human cornea, iris-ciliary body, choroid, retina, vitreous humor, and sclera tissues for 18 hours, no metabolites were observed.</paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9688b02f-8eae-4b2d-90c3-5d727d31c14a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
                  <content styleCode="bold">
		     
	NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250520"/>
               <component>
                  <section>
                     <id root="b5431f9f-4467-45c3-af8e-8ab67d0143e2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
		     
	<content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Animal studies have not been conducted to determine whether <content styleCode="bold">OZURDEX</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> </content>(dexamethasone intravitreal implant) has the potential for carcinogenesis or mutagenesis.  Fertility studies have not been conducted in animals. </paragraph>
                     </text>
                     <effectiveTime value="20250520"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b18f7b08-4db9-4d72-878d-a2f079d90cec"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
                  <content styleCode="bold">
		     
	CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Retinal Vein Occlusion</content>
                  </paragraph>
                  <paragraph>The efficacy of <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> </content>for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) was assessed in two, multicenter, double-masked, randomized, parallel studies.</paragraph>
                  <paragraph>Following a single injection, <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> demonstrated the following clinical results for the percent of patients with ≥ 15 letters of improvement from baseline in best-corrected visual acuity (BCVA): </paragraph>
                  <table>
                     <caption>Table 4: Number (Percent) of Patients with ≥ 15 Letters Improvement from Baseline in BCVA</caption>
                     <col width="100"/>
                     <col width="93"/>
                     <col width="87"/>
                     <col width="84"/>
                     <col width="91"/>
                     <col width="85"/>
                     <col width="83"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Study Day</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                              <content styleCode="bold">Study 1</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                              <content styleCode="bold">Study 2</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " align="center"/>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">OZURDEX</content>
                              <content styleCode="bold">
                                 <sup>® </sup>
                              </content>N=201</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Sham</content>
                              <br/>N=202</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">p-value*</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">OZURDEX</content>
                              <content styleCode="bold">
                                 <sup>® </sup>
                              </content>N=226</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Sham</content>
                              <br/>N=224</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">p-value*</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Day 30</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">40 (20%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">15 (7%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt; 0.01</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">51 (23%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">17 (8%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt; 0.01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Day 60</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">58 (29%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">21 (10%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt; 0.01</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">67 (30%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">27 (12%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt; 0.01</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Day 90</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">45 (22%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">25 (12%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt; 0.01</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">48 (21%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">31 (14%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.039</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Day 180</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">39 (19%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">37 (18%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.780</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">53 (24%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">38 (17%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.087</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>*P-values were based on the Pearson’s chi-square test.</paragraph>
                  <paragraph>In each individual study and in a pooled analysis, time to achieve ≥ 15 letters (3-line) improvement in BCVA cumulative response rate curves were significantly faster with <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> compared to sham (p &lt; 0.01), with <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>treated patients achieving a 3-line improvement in BCVA earlier than sham-treated patients.</paragraph>
                  <paragraph>The onset of a ≥ 15 letter (3-line) improvement in BCVA with <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> occurs within the first two months after<sup> </sup>implantation in approximately 20-30% of subjects. The duration of effect persists approximately one to three months after onset of this effect.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Posterior Segment Uveitis</content>
                  </paragraph>
                  <paragraph>The efficacy of <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> was assessed in a single, multicenter, masked, randomized study of 153 patients with non-infectious uveitis affecting the posterior segment of the eye.<content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>After a single injection, the percent of patients reaching a vitreous haze score of 0 (where a score of 0 represents no inflammation) was statistically significantly greater for patients receiving <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> versus sham at week 8 (primary time point) (47% versus 12%). The percent of patients achieving a 3-line improvement from baseline BCVA was 43% for patients receiving <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> versus 7% for sham at week 8.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Diabetic Macular Edema</content>
                  </paragraph>
                  <paragraph>The efficacy of <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> for the treatment of diabetic macular edema was assessed in two, multicenter, masked, randomized, sham-controlled studies. Subjects were to be evaluated for retreatment eligibility every three months starting from Month 6 but could only receive successive treatments at least 6 months apart.  Retreatment was based on physician’s discretion after examination including Optical Coherence Tomography. Patients in the <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>arm received an average of 4 treatments during the 36 months. </paragraph>
                  <paragraph>The primary endpoint was the proportion of patients with 15 or more letters improvement in BCVA from baseline at Month 39 or final visit for subjects who exited the study at or prior to Month 36. The Month 39 extension was included to accommodate the evaluation of safety and efficacy outcomes for subjects who received re-treatment at Month 36. Only fourteen percent of the study patients completed the Month 39 visit (16.8% from <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>and 12.2% from Sham).  </paragraph>
                  <table>
                     <caption>Table 5: Visual Acuity outcomes at Month 39 (All randomized subjects with LOCF<sup>c</sup>) </caption>
                     <col width="61"/>
                     <col width="254"/>
                     <col width="111"/>
                     <col width="111"/>
                     <col width="172"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Study</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Outcomes</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">O</content>
                              <content styleCode="bold">ZURDEX</content>
                              <content styleCode="bold">
                                 <sup>®</sup>
                              </content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Sham</content>
                              <br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Estimated Difference (95% CI)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">1<sup>a</sup>
                              <br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Mean (SD) Baseline BCVA (Letters)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">56 (10)<br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">57 (9)<br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Median (range) Baseline BCVA (Letters)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">59 (34-95)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">58 (34-74)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Gain of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">34 (21%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">19 (12%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">9.3% (1.4%, 17.3%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Loss of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">15 (9%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">17 (10%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">-1.1% (-7.5%, 5.3%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Mean change in BCVA (SD)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">4.1 (13.9)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.9 (11.9)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">3.2 (0.4, 5.9)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">2<sup>b</sup>
                              <br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">Mean (SD) Baseline BCVA (Letters)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">55 (10)<br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">56 (9)<br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule "/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Median (range) Baseline BCVA (Letters)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">58 (34-72)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">58 (36-82)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Gain of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">30 (18%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">16 (10%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">8.4% (0.9%, 15.8%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Loss of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">30 (18%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">18 (11%)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">7.1% (-0.5%, 14.7%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Mean change in BCVA (SD)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.4 (17.5)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0.8 (13.6)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">-0.7 (-4.1, 2.6)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a</sup>Study 1: <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup>, N=163; Sham, N=165</paragraph>
                  <paragraph>
                     <sup>b</sup>Study 2: <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup>, N=165; Sham, N=163</paragraph>
                  <paragraph>
                     <sup>c</sup>14% (16.8% from <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup> and 12.2% from Sham) of patients had BCVA outcome at Month 39, for the remaining patients, the data at Month 36 or earlier was carried forward.</paragraph>
                  <paragraph>Visual acuity outcomes by lens status (Phakic or Pseudophakic) at different visits are presented in Figure 2 and Figure 3. The occurrence of cataracts impacted visual acuity during the study. The visual acuity improvement from baseline increases during a treatment cycle, peaks at approximately 3 Months posttreatment and diminishes thereafter. Patients who were pseudophakic at baseline achieved greater mean BCVA change from baseline at the final study visit.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2</content>
                     <content styleCode="bold">:</content>
                     <content styleCode="bold"> Proportion of Subjects with ≥ 15 Letters Improvement from Baseline BCVA in the Study Eye</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000003"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 3</content>
                     <content styleCode="bold">:</content>
                     <content styleCode="bold"> Mean BCVA Change from Baseline</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000004"/>
                  </paragraph>
                  <paragraph>The best corrected visual acuity outcomes for the Pseudophakic and Phakic subgroups from Studies 1 and 2 at Month 39 are presented in Table 6.  </paragraph>
                  <table>
                     <caption>Table 6: Visual Acuity outcomes at Month 39 (Subgroup for pooled data with LOCF<sup>c</sup>)</caption>
                     <col width="108"/>
                     <col width="217"/>
                     <col width="114"/>
                     <col width="96"/>
                     <col width="174"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Subgroup</content>
                              <br/>
                              <content styleCode="bold">(Pooled)</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Outcomes</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">OZURDEX</content>
                              <content styleCode="bold">
                                 <sup>®</sup>
                              </content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Sham </content>
                              <br/>
                           </td>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Estimated Difference (95% CI)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <sup>a</sup>Pseudophakic</td>
                           <td styleCode="Toprule Lrule Rrule ">Gain of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule ">16 (20%)</td>
                           <td styleCode="Toprule Lrule Rrule ">11 (11%)</td>
                           <td styleCode="Toprule Lrule Rrule ">8.4% <br/>(-2.2%, 19.0%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Loss of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule ">4 (5%)</td>
                           <td styleCode="Toprule Lrule Rrule ">7 (7%)</td>
                           <td styleCode="Toprule Lrule Rrule ">-2.2% (-9.1%, 4.7%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Mean change in BCVA (SD)</td>
                           <td styleCode="Toprule Lrule Rrule ">5.8 (11.6)</td>
                           <td styleCode="Toprule Lrule Rrule ">1.4 (12.3)</td>
                           <td styleCode="Toprule Lrule Rrule ">4.2 (0.8, 7.6)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <sup>b</sup>Phakic</td>
                           <td styleCode="Toprule Lrule Rrule ">Gain of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule ">48 (20%)</td>
                           <td styleCode="Toprule Lrule Rrule ">24 (11%)</td>
                           <td styleCode="Toprule Lrule Rrule ">9.0% (2.7%, 15.4%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Loss of ≥15 letters in BCVA (n(%))</td>
                           <td styleCode="Toprule Lrule Rrule ">41 (17%)</td>
                           <td styleCode="Toprule Lrule Rrule ">28 (12%)</td>
                           <td styleCode="Toprule Lrule Rrule ">4.4% (-1.9%, 10.7%)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule "/>
                           <td styleCode="Toprule Lrule Rrule ">Mean change in BCVA (SD)</td>
                           <td styleCode="Toprule Lrule Rrule ">1.0 (16.9)</td>
                           <td styleCode="Toprule Lrule Rrule ">0.6 (12.9)</td>
                           <td styleCode="Toprule Lrule Rrule ">0.3 (-2.4, 3.0)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a</sup> Pseudophakic: <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup>, N=82; Sham, N=99</paragraph>
                  <paragraph>
                     <sup>b</sup> Phakic: <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup>, N=246; Sham, N=229</paragraph>
                  <paragraph>
                     <sup>c</sup>14% (16.8% from <content styleCode="bold">OZURDEX</content>
                     <sup>®</sup> and 12.2% from Sham) of patients had BCVA outcome at Month 39, for the remaining patients the data at Month 36 or earlier was used in the analysis.</paragraph>
               </text>
               <effectiveTime value="20250520"/>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Figure 2: Proportion of Subjects with ≥ 15 Letters Improvement from Baseline BCVA in the Study Eye </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>Figure 3: Mean BCVA Change from Baseline </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="179984a8-3f71-462d-94c7-d2bff74d309f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
                  <content styleCode="bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> </content>(dexamethasone intravitreal implant) 0.7 mg is supplied in a foil pouch with 1 single-use plastic applicator, NDC 0023-3348-07.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 15<sup>o</sup>C to 30<sup>o</sup>C (59<sup>o</sup>F to 86<sup>o</sup>F).</paragraph>
               </text>
               <effectiveTime value="20250520"/>
            </section>
         </component>
         <component>
            <section ID="_17_PATIENT_COUNSELING">
               <id root="c441ccb4-a27f-4d81-a276-9883b0fe181b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
                  <content styleCode="bold">
		     
	PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Steroid-related Effects </content>
                  </paragraph>
                  <paragraph>Advise patients that a cataract may occur after repeated treatment with <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>. If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the cataract and restore their vision.  </paragraph>
                  <paragraph>Advise patients that they may develop increased intraocular pressure with <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content> treatment, and the increased IOP will need to be managed with eye drops, and, rarely, with surgery.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Intravitreal Injection-related Effects</content>
                  </paragraph>
                  <paragraph>Advise patients that in the days following intravitreal injection of <content styleCode="bold">OZURDEX</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>, patients are at risk for potential complications including in particular, but not limited to, the development of endophthalmitis or elevated intraocular pressure. </paragraph>
                  <paragraph>
                     <content styleCode="underline">When to Seek Physician Advice</content>
                  </paragraph>
                  <paragraph>Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Driving and Using Machines </content>
                  </paragraph>
                  <paragraph>Inform patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machines until this has been resolved.</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>AbbVie Inc.<br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2025 AbbVie. All rights reserved.</paragraph>
                  <paragraph>OZURDEX and its design are trademarks of Allergan, Inc., an AbbVie company.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000005"/>
                  </paragraph>
                  <paragraph>V5.0USPI3348</paragraph>
               </text>
               <effectiveTime value="20250520"/>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>Shape

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="548656cf-b94d-4728-877f-6f77da3d8f54"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0023-3348-07<br/>Ozurdex<sup>®</sup>
                     <br/>(dexamethasone<br/>intravitreal implant) 0.7 mg<br/>
                     <content styleCode="bold">Allergan</content>
                     <br/>For Intravitreal Injection<br/>Contents include:<content styleCode="bold"> </content>
                     <br/>
                     <content styleCode="bold">One Sterile, Use Applicator</content>
                     <br/>Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000006"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250520"/>
               <component>
                  <observationMedia ID="MM02000006">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0023-3348-07
Ozurdex®
(dexamethasone
intravitreal implant) 0.7 mg
Allergan
For Intravitreal Injection
Contents include: One  Sterile, Use Applicator
Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ozurdex-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>